Cartesian Therapeutics, Inc. RNAC
Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026
Cartesian Therapeutics, Inc. (RNAC) is a healthcare company listed in the US with a market value of about $194M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$127M, a net margin of -12435.2%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -30% a year, a 5-year average ROIC of -161%.
About Cartesian Therapeutics
Cartesian Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. Revenue went from $3M in 2014 to $3M in 2025, a decline of about 0.8% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 434% over three years (dilution for shareholders). It spends 2075% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $3M | $39M | $26M | $111M | $85M | $17M | $7M | $903000 | $207000 | $8M |
| Net income | -$127M | -$130M | -$77M | -$220M | $35M | -$26M | -$69M | -$55M | -$65M | -$65M | -$36M |
| Free cash flow | -$90M | -$79M | -$33M | -$51M | -$33M | -$61M | $34M | -$51M | -$60M | -$53M | -$20M |
| EPS (diluted) | $-4.95 | $-5.02 | $-4.49 | $-49.76 | $3.00 | $-6.60 | $-20.40 | $-36.60 | $-87.60 | $-96.00 | $-116.70 |
| Net margin | -12435.2% | -4658.6% | -199.0% | -844.9% | 31.9% | -30.2% | -415.0% | -829.0% | -7235.4% | -31556.0% | -448.0% |
| ROIC | — | — | -482.9% | — | 10.9% | -11.3% | — | -598.2% | — | -97.2% | -49.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Cartesian Therapeutics pay a dividend?
Not currently.
Is Cartesian Therapeutics a good stock to buy?
We do not give buy or sell advice. Cartesian Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.